Anokion is an innovative immune tolerance company based in Cambridge, MA, dedicated to revolutionizing the treatment of autoimmune diseases. Their proprietary immune tolerance platform utilizes engineered proteins to deliver targeted therapy for antigen-mediated diseases, offering a more effective approach without the drawbacks of broad immunosuppression.
With a focus on harnessing the body's natural tolerance pathways, Anokion's antigen-specific platform has the potential to transform autoimmune therapy and address a wide range of clinical applications. Their groundbreaking research and development efforts have been recognized through publications in prestigious scientific journals, further validating their immune tolerance approach to treating diseases such as celiac disease and multiple sclerosis.
Generated from the website